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This systematic review evaluates the utility of maternal Placental Growth Factor (PlGF) when 
measured in late pregnancy (>20 weeks) as a predictor of adverse obstetric and perinatal outcomes.  
Methods 
Pubmed and Embase were searched using the term “placental growth factor” in combination with 
relevant perinatal outcomes. Studies were included if they measured PlGF levels in pregnant women 
after 20+0 weeks gestation and reported relevant adverse obstetric or perinatal outcomes related to 
placental insufficiency (excluding pre-eclampsia).   
Results 
Twenty-six studies were eligible for inclusion with 21 studies investigating the relationship between 
PlGF and small for gestational age (SGA) and 7 studies investigating PlGF for the prediction of other 
adverse perinatal outcomes.  In all studies, maternal PlGF levels were significantly lower in the SGA 
group compared to controls. Other outcomes investigated included caesarean section (CS) for fetal 
compromise, low Apgar score, neonatal intensive care unit (NICU) admission, neonatal acidosis, 
stillbirth, and intrapartum fetal compromise. The results generally showed a significant association 
between low PlGF levels and CS for fetal compromise, NICU admission and stillbirth.   
Conclusion 
Low maternal PlGF levels in late pregnancy are strongly associated with SGA. Findings across studies 
were variable in relation to PlGF and the prediction of other adverse intrapartum and perinatal 
outcomes, however there was a consistent association between low PlGF levels and CS for fetal 
compromise, NICU admission and stillbirth. This review suggests that the use of PlGF for the prediction 
of adverse outcomes is promising. Its predictive value may potentially be enhanced if used in 
combination with other biomarkers or biophysical measures of fetal well-being.  
 
Keywords: Placental growth factor; PlGF; perinatal outcomes; small for gestational age  
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INTRODUCTION 
Over recent years there have been a large number of studies which have provided strong 
evidence that levels of placentally derived angiogenic proteins are perturbed particularly in women 
who develop pre-eclampsia (1-7) as well as other obstetric and perinatal complications (8-12). Many, 
if not all of these conditions share a similar aetiology characterised by placental dysfunction.  
One such protein is Placental Growth Factor (PlGF), levels of which are reduced in women with 
poor perinatal outcomes (8, 13, 14). PlGF is a member of the vascular endothelial growth factor (VEGF) 
family and was first isolated from the human placenta in 1991 (15). Although the precise mechanisms 
by which PlGF exerts its various effects are still unclear it is known to play a pivotal role in angiogenesis 
and vasculogenesis, both vital steps for the creation of a low resistance placental circulation (16).  
In normal pregnancy, maternal PlGF levels have a non-linear association with gestation, peak 
at around 30 weeks and then progressively fall towards term (17, 18). During the first and second 
trimesters of pregnancy, low levels of PlGF are linked to impaired placental development and 
angiogenesis, which is associated with various pregnancy complications including pre-eclampsia, 
miscarriage, stillbirth, low birth weight and fetal growth restriction (FGR) (12, 16, 19, 20). More 
recently, low maternal PlGF levels in the third trimester appear to be associated with late onset FGR, 
gestational hypertension and pre-eclampsia as well as intrapartum fetal compromise and adverse 
perinatal outcomes (8, 21).  
The aim of this systematic review was to evaluate the utility of maternal Placental Growth 
Factor (PlGF) levels when measured in late pregnancy (>20 weeks) as a predictor of adverse obstetric 
and perinatal outcomes other than pre-eclampsia.  
 
METHODOLOGY 
Data Sources  
The search strategy was developed in accordance with the Centre for Reviews and 
Disseminations’ Guidance for Systematic Reviews in Health Care (22) and the Preferred Reporting 
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Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines (23). The PubMed and Embase 
databases were searched for papers published between January 1997 and June 2017 using the key 
words: (“PLGF” OR “placental growth factor”) AND (“neonat*” OR “perinat*” OR “intrapartum” OR 
“SGA” OR “small for gestational age” OR “FGR” OR “fetal growth restriction” OR “growth restriction” 
OR “IUGR”). The search was restricted to English as the language, human as the species and female as 
the gender. The Cochrane Library and Clinicaltrials.gov databases were also searched to identify any 
relevant reviews or studies.  
Study Selection 
An initial title and abstract review was performed on all publications from the search to 
exclude duplicated and ineligible manuscripts. The first reviewer (HS) screened all titles and extracted 
those citations requiring more detailed examination. A second review of abstracts and citations was 
then performed by two reviewers (HS and LD) who went on to read and select all relevant studies for 
inclusion and extract the study data. When any disagreement between the opinions of the two 
reviewers arose, a further assessment of that study was performed by a third reviewer (SK). Studies 
were eligible for inclusion if they reported maternal PlGF levels in pregnant women >20+0 weeks 
gestation and relevant obstetric or perinatal outcomes (excluding pre-eclampsia) or the association 
between low maternal PlGF levels and adverse outcomes. The adverse outcomes included in the 
review were those that could be putatively linked to underlying placental insufficiency. The gestational 
age cut-off (>20+0 weeks) was chosen to reflect placental insufficiency developing in later pregnancy. 
This threshold has also been used by other investigators (10). Specific obstetric and perinatal 
outcomes investigated were, small for gestational age, fetal growth restriction, preterm birth, 
intrapartum fetal compromise, emergency caesarean delivery for fetal distress, stillbirth, neonatal 
acidosis and NICU admission. All selected full-text manuscripts were then reviewed in detail. A manual 
search of the reference lists of these articles was carried out to identify relevant papers not captured 
by the initial search strategy. Systematic and expert reviews, case series and reports, abstracts, book 
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chapters, opinion pieces and guidelines were excluded. Publications were also excluded if they only 
reported PlGF solely in relation to pre-eclampsia or if PlGF was only measured at <20 weeks gestation. 
The specific outcomes investigated in this systematic review were: small for gestational age 
(SGA), FGR, preterm birth, intrapartum complications (fetal compromise, emergency operative birth) 
and neonatal complications (low Apgar score at 5 minutes, neonatal intensive care unit admission 
(NICU), acidosis) and stillbirth. 
 
RESULTS 
Figure 1 outlines the PRISMA flow chart for the identification of relevant studies for this 
review. Three hundred and forty-three publications were initially identified using the aforementioned 
search strategy and 44 full text articles were then reviewed. Twenty-six studies (total participants, N 
= 42,609) were deemed to be eligible for final inclusion. Of these, 21 studies reported the relationship 
between PlGF and SGA or FGR infants with a participant total of N = 41,837 (10, 13, 24-42), seven 
studies detailed the predictive value of PlGF for other adverse perinatal outcomes with a participant 
total of N = 13,401 (8, 10, 13, 14, 25, 38, 43) and three studies described the role of PlGF in 
distinguishing between placentally-mediated FGR and constitutionally SGA infants with a participant 
total of N = 841 (10, 44, 45).  
Study characteristics are presented in Table 1 and include the type of study, populations of 
recruited women, total number of participants, gestation at which PlGF was measured, type of PlGF 
assay, criteria for abnormal maternal PlGF levels if defined and specific outcomes investigated. Most 
studies were prospective cohort by design (10, 13, 14, 24, 25, 27-32, 35-38, 40, 43, 44). There were 
seven either nested or retrospective case-control studies (26, 33, 34, 39, 41, 42, 45) and one 
prospective cross-sectional (8). The majority of studies recruited participants with uncomplicated 
pregnancies (8, 13, 14, 24-26, 29, 31-34, 36-38, 41, 42) with seven of these recruiting from the third 
trimester only. Five studies recruited participants with a suspected or confirmed SGA fetus on 
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antenatal ultrasound (10, 30, 39, 44, 45), two recruited those at risk of either FGR or pre-eclampsia 
(27, 43), and one study recruited women with abnormal uterine artery Dopplers (40). Two studies 
investigated specific populations - women with Type 1 Diabetes Mellitus (35) and those living at high 
altitude (28). Participant numbers in the individual studies ranged from N = 31 in a small retrospective 
case-control study (39) to N = 9850 in a large prospective cohort study (32).  
Although all the included studies collected PlGF samples >20 weeks gestation, eight studies 
collected samples exclusively in the third trimester (>30 weeks gestation) (8, 13, 14, 25, 26, 31, 32, 
44). The included studies used a variety of PlGF assay platforms from various manufacturers - R&D 
Systems® (14, 24, 26, 27, 35, 38-42, 44), Roche Diagnostics® (13, 25, 28, 29, 31, 32, 34, 36), Alere® (8, 
10, 30, 43, 45), PerkinElmer® (37) and BRAHMS KRYPTOR® (33). Only half of the included studies 
reported the definition of an abnormal PlGF criterion (10, 13, 14, 24, 25, 29-32, 38, 40, 43, 45); of 
these the majority used <5th centile for gestational age as the defined threshold (10, 13, 25, 29-32, 
45). Most studies reported median PlGF levels (8, 24, 29-32, 34-36, 42, 45), some reported the mean 
and standard deviation (SD) (26, 28, 39-41), others used multiples of the median (MoM) (13, 14, 25, 
33, 37, 44) and two studies calculated logarithmic means (27, 38). Individual studies did not routinely 
report gestation-specific PlGF ranges for their study cohorts.  
Small for gestational age  
The association between maternal PlGF levels and SGA or FGR was reported in 21 studies 
(Table 2). The definition of SGA or FGR varied between studies. Most studies defined SGA as birth 
weight (BW) <10th centile (13, 24-26, 28, 35-37, 39, 42), four studies used BW <5th centile (29, 31-33) 
and two used BW <3rd centile (10, 30). Three studies defined FGR as an estimated fetal weight (EFW) 
of <10th or <5th centile plus another ultrasound marker of placental dysfunction (Umbilical Artery 
Pulsatility Index >90-95th centile, Cerebroplacental Ratio <5th centile or oligohydramnious/amniotic 
fluid index <10th centile) (27, 34, 40) and the final study used a unique definition (BW two standard 
deviations or more below expected weight) (41).  
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Twenty studies compared PlGF levels between the SGA group and controls. However, one 
study (10) compared the study cohort (PlGF <5th centile) to those with normal levels and found 
significantly more infants with BW <3rd centile in the low PlGF group. Maternal PlGF levels were 
significantly lower in the SGA group compared to the “normal” or control cohorts in 16 out of 20 
studies (13, 24-29, 31-34, 37-39, 41, 42), not significant in three studies (35, 36, 40) and not specifically 
reported in one study (30). The three studies that reported a non-significant difference in maternal 
PlGF levels all had relatively low numbers in their SGA cohorts. Of the studies investigating the 
association between late-pregnancy PlGF and SGA, six reported additional predictive values (outlined 
in Table 2), including area under the receiver-operator characteristic (AUROC) curves, ranging from 
0.66 to 0.76 (24, 30, 33, 37); sensitivity (range: 36% - 100%)/specificity (range: 54% - 88.7%)/positive 
predictive value (PPV)/negative predictive value (NPV) (24, 30, 40), odds ratio (OR) (13) and detection 
rates (DR) ranging from 23% to 33% (33, 37).  
Constitutionally SGA versus FGR 
Three papers investigated the role of PlGF in discriminating between placentally-mediated 
FGR and constitutionally-SGA fetuses (10, 44, 45). In all three studies placentally-mediated FGR was 
defined post-hoc by identifying placentae with histological lesions indicative of under perfusion. 
Benton et al (45) found a significant difference in the proportion of women with low PlGF levels (<5th 
centile) between cases of placental FGR, constitutionally SGA and normal controls . In a cohort of 122 
SGA suspected fetuses, Triunfo et al (44) found 70 cases (57.4%) to have signs of placental under 
perfusion. Maternal PlGF levels in this group were significantly lower than the control cohort (0.21 
MoM vs. 0.55 MoM, p= 0.002). Furthermore, multivariate analysis showed that lower maternal PlGF 
levels had a significant independent relationship with features of placental under perfusion [OR 0.2 
(95%CI 0.05-0.82), p=0.026].  In a cohort of 213 antenatally suspected FGR pregnancies, Benton et al 
(10) found 44.1% (94/213) of cases to have a low PlGF (<5th centile). A significantly higher proportion 
of pregnancies with a low PlGF were found to have placental FGR compared to those with a normal 
PlGF (58.5% vs. 0.8%, p<0.001). The performance characteristics for a low maternal PlGF level to 
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identify cases of placental FGR was reported as sensitivity 98.2% (95% CI 90.5-99.9), specificity 75.1% 
(95% CI 67.6-81.7), positive predictive value 58.5% (95% CI 47.9-68.6), and negative predictive value 
99.2% (95%CI 95.4-99.9) with an AUROC curve of 0.96 (95%CI 0.93-0.98). 
Other adverse obstetric or perinatal outcomes  
Seven studies investigated the relationship between late-pregnancy PlGF and obstetric or 
perinatal outcomes other than SGA (Table 3), with Benton et al reporting two separate data set 
analyses - one a placental pathology-based analysis (referred to in later text as ‘placental analysis’) 
and the other a sample-to-delivery interval analysis (referred to in later text as ‘delivery analysis’) (10). 
Outcomes reported included caesarean section (CS) for fetal compromise (8, 10, 13, 25, 43), five-
minute Apgar score <7 (8, 10, 13, 25), NICU admission (8, 10, 13, 25), neonatal acidosis (8, 13, 25, 43), 
stillbirth (10, 13), preterm birth (10, 38), intrapartum fetal compromise (defined as intrapartum fetal 
heart rate abnormalities and/or abnormal fetal scalp lactate requiring emergency delivery) (8) and an 
adverse composite neonatal outcome (8, 14). The groups compared and the way in which results were 
presented varied widely between the studies. 
All studies investigating CS for fetal compromise either reported an increased frequency of 
this outcome in association with a low PlGF (<5th centile) or found that the cohort in which the 
outcome occurred had lower PlGF levels. However not all studies reported significant differences 
between the various cohorts. Benton et al (10) found for both their reported analyses that a 
significantly higher proportion of women with CS for fetal compromise had low PlGF levels (<5th 
centile) (29.8% vs. 8.4%, p<0.001 (placental analysis) and 36.1% vs. 7.5%, p<0.001 (delivery analysis)). 
Similarly, Valino et al found in both their studies (13, 25) that the maternal PlGF levels were 
significantly lower in the group requiring an emergency CS for fetal compromise prior to the onset of 
labour (0.24MoM vs. 0.95MoM, p<0.0001 and 0.34MoM vs. 0.98MoM, p<0.01; respectively). 
However, there was no difference in maternal PlGF levels between cases of emergency CS for fetal 
compromise during labour compared to controls. In contrast, Bligh et al (8) demonstrated that women 
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who developed intrapartum fetal compromise requiring emergency operative delivery had 
significantly lower median PlGF levels (90pg/ml vs. 139pg/ml, p=0.003).  
For Apgar <7 at five minutes, findings varied between the four studies reporting this outcome. 
Benton et al (10) reported that a significantly higher proportion of low Apgar scores was associated 
with a low maternal PlGF levels (12.8% vs. 0.8%, p<0.001 (placental analysis) and 8.9% vs. 0.8%, 
p<0.001 (delivery analysis)). Similarly, Bligh et al (8) found that the cohort with a low Apgar score had 
a significantly lower median maternal PlGF level (80pg/ml vs. 128pg/ml, p=0.02). Conversely, Valino 
et al found in both their studies (13, 25) a higher PlGF MoM in the groups with a low Apgar score; 
however this difference was not significant. All studies investigating NICU admission either reported 
an increased occurrence of this outcome in association with a low PlGF or found that the group in 
which the outcome occurred had a lower PlGF value, however again, not all findings were significant. 
With regards to neonatal acidosis, only one (8) of four studies found a significant association. Bligh et 
al (8) reported a significantly lower median maternal PlGF levels in the group with acidosis (defined as 
cord umbilical artery pH≤7.1 and/or lactate ≥ 6mmol/L) when compared to those without (94pg/ml 
vs. 132pg/ml, p=0.02).  
 Two studies reported stillbirth as an outcome. Benton et al (10) found a significantly higher 
proportion of stillbirths occurred in the group with PlGF levels <5th centile (6.4% vs. 0%, p<0.05 
(placental analysis) and 3.8% vs. 0.4%, p<0.05 (delivery analysis)). Valino et al (25) reported that 
although the group in which stillbirths occurred had lower maternal PlGF levels this difference was 
not significant. Two studies also reported preterm birth (PTB) (defined as <37 completed weeks 
gestation) as an outcome. Benton et al (10) found that a significantly higher proportion of preterm 
deliveries occurred in the cohort with a low maternal PlGF level (61.7% vs. 18.5%, p<0.001 (placental 
analysis) and 50.3% vs. 13.0%, p<0.001 (delivery analysis)). Mijal et al (38) reported non-significant 
adjusted odds ratios for both spontaneous PTB [1.12 (95% CI 0.69-1.83)] and for medically indicated 
PTB [1.32 (95%CI 0.56-3.09)] associated with a low maternal PlGF level (defined as <25th centile).  
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Bligh et al (8) reported the association between lower maternal PlGF levels (94pg/ml vs. 
140pg/ml, p=0.002) with an adverse composite neonatal outcome (defined as acidosis, Apgar ≤7 at 5 
minutes or admission to NICU). Similarly, Lobmaier et al (14) found that in a cohort of SGA pregnancies 
a significantly greater proportion of composite outcomes (defined as operative delivery for non-
reassuring fetal status or neonatal acidosis) occurred in the group with a low maternal PlGF level 
(defined as <0.125MoM) (45% vs. 28%, p<0.05).   
DISCUSSION 
The results from this systematic review show a clear and generally consistent association of 
lower PlGF levels with a variety of obstetric complications (other than pre-eclampsia), intrapartum 
complications and adverse perinatal outcomes. We found that women with SGA fetuses had lower 
PlGF levels when compared to controls. Low maternal PlGF levels in late pregnancy has a potential 
role in distinguishing placentally-mediated FGR from constitutionally SGA fetuses with a recent study 
showing very good discrimination capacity (AUROC >0.95) using a threshold of the <5th centile for 
identifying placental FGR (10).  Again, only a small number of studies (7 in total) (8, 10, 13, 14, 25, 38, 
43) investigated the association between PlGF levels and other adverse perinatal outcomes with 
varying results. However, a consistent association was found in all studies for low PlGF levels and CS 
for fetal compromise, NICU admission and stillbirth.  
Placental growth factor is predominately synthesised by trophoblasts and plays a key role in 
placental vasculogenesis and angiogenesis. Pre-eclampsia and early-onset fetal growth restriction are 
characterised by placental dysfunction, a pro-inflammatory and relatively hypoxic intrauterine 
environment (46, 47). When exposed to hypoxia, trophoblasts undergo apoptosis resulting in 
cessation of PlGF synthesis (20, 48-50). In the setting of hypertensive disorders of pregnancy, a recent 
review by Ukah et al demonstrated that lower PlGF levels were predictive of poorer neonatal 
outcomes and preterm birth (1).  Recent literature also suggests that a similar hypoxic process 
secondary to suboptimal placental function and reflected by lower levels of maternal PlGF may also 
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be present later in pregnancy causing late-onset FGR and intrapartum fetal compromise culminating 
in adverse neonatal outcomes (8, 13, 44).  
 The ability of maternal PlGF to predict adverse perinatal outcomes may be improved by 
combining it with ultrasound and Doppler parameters. Screening in late-pregnancy with a 
combination of angiogenic factors and feto-placental Dopplers has been found to be predictive of FGR 
(26, 28). Similarly, in the third trimester, the incorporation of maternal PlGF levels, specific maternal 
characteristics and estimated fetal weight (EFW) improves the prediction of SGA (31, 32). Another 
Doppler parameter that shows promise in a combined predictive model is the cerebroplacental ratio 
(CPR) which is reflective of both suboptimal placental function and compensatory fetal cerebral 
perfusion (51, 52). Prior et al (53) demonstrated that in term appropriately grown fetuses, a low CPR 
was predictive of intrapartum fetal compromise and an increased likelihood of delivery by emergency 
caesarean section for fetal distress. More recently, Bligh et al (54) showed that emergency caesarean 
for fetal compromise at term was better predicted using a combination of the fetal CPR and maternal 
PlGF than either marker alone.  
 Although PlGF appears to have promise as a predictive marker for not just pre-eclampsia but 
other adverse outcomes as detailed in this systematic review, there is still much about its biology that 
is unknown. The impact that circadian variation, fetal gender, maternal ethnicity and the secretion of 
soluble receptors (55) may have on circulating levels of maternal PlGF throughout pregnancy is 
currently unclear. A substantial proportion (up to 30%) of measured serum PlGF is also believed to 
result from extraplacental peripheral cell secretion and thus may not necessarily reflect changes in 
placental production and function (56). Additionally, many studies investigating angiogenic factors in 
pregnancy use the sFlt-1/PlGF ratio in predictive models rather than PlGF alone, although it is not clear 
if this approach is any better in screening performance. Currently, there is insufficient evidence to 
recommend a preferred PlGF assay, thresholds for abnormality or optimal gestation for measurement 
in order to predict adverse outcomes, especially in an otherwise low risk population. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
12 
 
 Limitations of this systematic review include the lack of randomised control trials and the fact 
that a considerable proportion of the data came from retrospective studies with significant 
methodological heterogeneity. Additionally, by excluding preeclampsia from our specific search terms 
it is possible that we may have excluded some studies that included a cohort or subset of data 
investigating PlGF levels and FGR without concurrent preeclampsia. However, our search strategy did 
include terms reported in either the title and/or abstract and with this caveat we were likely to have 
identified the majority of studies reporting FGR or SGA as independent outcomes. Indeed a number 
of reviewed articles did include preeclampsia cases in their study designs (27, 33, 34, 36, 43). 
Preeclampsia and FGR are both considered disorders of placental dysfunction and both have an 
association with lower PlGF levels (16, 20, 57). Levine et al found that PlGF levels were lower in women 
who developed preeclampsia associated with a SGA infant compared with an appropriate for 
gestational age (AGA) infant (7). Studies have also shown lower PlGF levels in normotensive women 
delivering a SGA infant compared to normotensive women with an AGA infant (41, 42, 58). However, 
SGA infants may simply be constitutionally small without any element of placental dysfunction and 
thus lower PlGF levels may not always be observed (10, 44). When evaluating SGA infants, the 
presence or absence of preeclampsia is therefore likely to impact the PlGF levels observed. More 
research is needed to be able to determine the magnitude of this impact.  
To the best of our knowledge this is the first systematic review investigating the relationship 
between PlGF measured after 20 weeks gestation and adverse perinatal outcomes other than pre-
eclampsia. Despite the identified limitations of the review, the results presented demonstrate that 
low PlGF is associated with SGA, FGR, caesarean delivery for fetal compromise and stillbirth. Future 
research should focus on the role of PlGF in combination with other biomarkers and/or ultrasound 
parameters for the prediction of adverse perinatal outcomes.  
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Figure 1 – Selection of studies 
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Table 1. Study characteristics  
Study  Type Population   Total N*  PlGF 
gestatio
n 
(weeks) 
PlGF assay  Abnorm
al PlGF 
criteria 
Outcomes 
investigate
d 
Cetin 2017 
(43) 
Prospective 
cohort  
At risk of FGR 
or PET 
16 19-35  Triage 
(Alere) 
very low 
<12; low 
12-100 
pg/ml 
emCS, 
Acidosis  
Furuta 
2017 (24) 
Prospective 
cohort 
Uncomplicate
d 
183 24-27  ELISA (R&D 
Systems) 
<10th  SGA 
Benton 
2016 (10) 
Prospective 
cohort 
SGA on 
antenatal USS 
213 
(placent
al 
analysis) 
+ 
411 
(delivery 
analysis) 
>20  Triage 
(Alere) 
<5th a SGA 
Plac FGR v 
SGA 
PTB, emCS, 
Stillbirth, 
Apgar, 
NICU, [PET] 
Bligh 2016 
(8) 
Prospective 
cross-
sectional 
Uncomplicate
d 3rd trimester 
342 >36  Triage 
(Alere) 
N/A IFC, 
Acidosis, 
Apgar, 
NICU, 
Composite 
Kienast 
2016 (28) 
Prospective 
cohort 
Uncomplicate
d, living at 
high-altitude 
346 18-25; 
28-32 
ELECSYS 
(Roche 
Diagnostics) 
N/A SGA 
Kwiatkows
ki 2016 
(27) 
Prospective 
cohort 
PET or FGR 
(cases) 
84  22-41 ELISA N/A FGR 
Triunfo 
2016 (26) 
Nested 
case-control 
Uncomplicate
d 3rd trimester 
160 
(nested) 
32-36 ELISA (R&D 
Systems) 
N/A SGA 
Valino 
2016 (13) 
Prospective 
cohort 
Uncomplicate
d 3rd trimester 
8268 30+0-
34+6 
Cobas e411 
(Roche 
Diagnostics) 
<5th; 
<10th  
 
SGA 
emCS, 
Stillbirth, 
Acidosis, 
Apgar, 
NICU, [PET] 
Valino 
2016 (25) 
Prospective 
cohort 
Uncomplicate
d 3rd trimester 
3953 35+0-
37+6 
Cobas e411 
(Roche 
Diagnostics) 
<5th  SGA 
emCS, 
Acidosis, 
Apgar, 
NICU 
Bakalis 
2015 (32) 
Prospective 
cohort 
Uncomplicate
d 3rd trimester 
9850 30+0-
34+6 
Cobas e411 
(Roche 
Diagnostics) 
<5th; 
<10th  
SGA 
Fadigas 
2015 (31) 
Prospective 
cohort 
Uncomplicate
d 3rd trimester 
3859 35+0-
37+6 
Cobas e411 
(Roche 
Diagnostics) 
<5th; 
<10th  
SGA 
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Griffin 
2015 (30) 
Prospective 
cohort 
Antenatally 
suspected 
SGA 
592 34 
(median
) 
Triage 
(Alere) 
<5th b SGA 
Lesmes 
2015 (29) 
Prospective 
cohort 
Uncomplicate
d 2nd 
trimester 
9715 19-24 Cobas e411 
(Roche 
Diagnostics) 
<5th; 
<10th  
SGA 
Gutaj 2014 
(35) 
Prospective 
cohort 
T1DM 59 22-25; 
pre-
delivery 
ELISA (R&D 
Systems) 
N/A SGA 
Herraiz 
2014 (34) 
Nested 
case-control  
Uncomplicate
d  
198  >24 ELECSYS 
(Roche 
Diagnostics) 
N/A FGR 
Lobmaier 
2014 (14) 
Prospective 
cohort 
Uncomplicate
d 3rd trimester 
198 30-40 ELISA (R&D 
Systems) 
<0.125 
MoM 
Composite, 
[PET] 
Nucci 2014 
(33) 
Nested 
case-control 
Uncomplicate
d 
393  20-24; 
30-34 
BRAHMS 
KRYPTOR 
N/A SGA  
[PET] 
Triunfo 
2014 (44) 
Prospective 
cohort 
SGA on 
antenatal USS 
122 30-34 ELISA (R&D 
Systems) 
N/A Plac FGR v 
SGA 
 
Boucoiran 
2013 (37) 
Prospective 
cohort 
Uncomplicate
d 
772 24-26 DELFIA 
Xpress 
(PerkinElme
r) 
N/A SGA 
[PET] 
Rizos 2013 
(36) 
Retrospectiv
e case-
control  
Uncomplicate
d 
104  20-26; 
28-35 
ELECSYS 
(Roche 
Diagnostics) 
N/A SGA 
[PET] 
Benton 
2012 (45) 
Retrospectiv
e case-
control 
Antenatally 
diagnosed 
FGR 
95 23+0-
36+6 
Triage 
(Alere) 
<5th b Plac FGR v 
SGA 
 
Mijal 2012 
(38) 
Prospective 
(sub) cohort 
Uncomplicate
d 
933 15-27 
(22.4 
mean) 
ELISA <25th c SGA 
PTB 
Stepan 
2007 (40) 
Prospective 
cohort 
Abnormal UtA 
on antenatal 
USS 
63 19-24 ELISA (R&D 
Systems) 
Cut-off 
79.3 
pg/ml 
FGR 
[PET] 
Wallner 
2007 (39) 
Retrospectiv
e case-
control 
SGA on 
antenatal USS 
31 33 
(median
) 
ELISA (R&D 
Systems) 
N/A SGA 
Bersinger 
2004 (41) 
Nested 
case-control  
Uncomplicate
d 
90 
(nested) 
25; 33 ELISA (R&D 
Systems) 
N/A SGA 
[PET] 
Taylor 
2003 (42) 
Retrospectiv
e case-
control 
Uncomplicate
d 
36 
(cross-
section)  
34.8 
(mean) 
ELISA (R&D 
Systems) 
N/A SGA 
[PET] 
FGR – fetal growth restriction; PET – pre-eclampsia; SGA – small for gestational age; USS – ultrasound scan; 
T1DM – Type 1 Diabetes Mellitus; UtA – Uterine Artery (Dopplers); PlGF – Placental Growth Factor; emCS – 
emergency caesarean section; PTB – preterm birth; NICU – Neonatal Intensive Care Unit; Plac FGR – 
placentally-mediated FGR; IFC – intrapartum fetal compromise; N/A – data not available; <5th, <10th, <25th – 
centile for gestational age.  
* Number includes cases with adverse outcome (apart from PET) plus any normal or control cases. 
a as defined in Saffer et al, 2013 (17) 
b as defined in Knudsen et al, 2012 (59) 
c of term, normal pregnancies  
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Table 2. Association between PlGF and small for gestational age  
Study  Definition 
SGA/FGR 
Groups compared 
(n=) 
Key result Significant 
relationship  
Predictive 
values 
Furuta 2017 
(24) 
SGA: BW <10th  (1) SGA (n=13)  
(2) non-SGA (n=170) 
Median PlGF:  
(1) = 365 vs (2) = 
535. 
Yes 
p=0.0018 
PlGF cut-off 
of 500:  
Sens = 100%   
Spec = 54%   
PPV = 14%   
NPV = 100%  
AUROC for 
SGA = 0.76 
Benton 
2016 (10) 
BW <3rd  (1) Low PlGF <5th 
centile (n=94)  
(2) Normal PlGF 
(n=119)  
BW <3rd n (%): 
(1) 55 (58.5%) vs 
(2) 35 (29.4%) 
Yes 
p<0.001 
N/A 
Kienast 
2016 (28) 
FGR: BW <10th  (1) FGR (n=26)  
(2) Controls (n=272) 
Mean ±SEM 
(range) PlGF: 18-
25wks: (1) = 264 
±113 (89-504) vs 
(2) = 432 ±251 (92-
1813). 
28-32wks: (1) = 
498 ±351 (72-
1529) vs (2) = 790 
±449 (183-3209).  
Yes 
18-25wks: 
p<0.05 
28-32wks: 
p<0.05 
N/A - only 
sFlt-1/PlGF 
ratio 
reported 
Kwiatkowski 
2016 (27) 
FGR: EFW<10th 
+ UA-PI>95th or 
CPR<5th 
(1) FGR (n=41)  
(2) control (n=43) 
Mean ±SD log 
PlGF:  
(1) = 1.93 ±0.48 vs 
(2) = 2.58 ±0.32.  
Yes 
p<0.0001 
N/A 
Triunfo 
2016 (26) 
SGA: BW <10th  (1) SGA (n=80)  
(2) AGA controls 
(n=80) 
Mean ±SD PlGF:  
(1) = 518.39 
±492.91 vs (2) = 
703.94 ±516.64 
Yes 
p=0.021 
N/A - only 
reported for 
sFlt-1/PlGF 
ratio 
Valino 2016 
(13) 
SGA: BW <10th  (1) SGA delivery 
<37w (n=60) 
(2) SGA delivery 
≥37w (n=762) 
(3) Unaffected 
(n=7207) 
Median (IQR) 
MoM:  
(1) = 0.33(0.16-
0.61), (2) = 
0.64(0.38-1.06), 
(3) = 1.01(0.63-
1.57) 
Yes 
p<0.0001 
PlGF log10 
MoM for 
prediction 
of SGA 
>37w: 
OR(95%CI) = 
0.20(0.15-
0.26), 
P<0.0001 
Valino 2016 
(25) 
SGA: BW <10th  (1) SGA (n=379)  
(2) Unaffected 
(n=3509) 
Median (IQR) 
MoM:  
(1) = 0.66(0.37-
1.15) vs (2) = 
1.02(0.59-1.79) 
Yes 
p<0.0001 
N/A - only 
reported in 
combination 
with other 
factors  
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Bakalis 
2015 (32) 
SGA: BW <5th  (1) SGA delivering <5 
weeks following 
assessment (n=57)  
(2) SGA <5th 
delivering ≥5 weeks 
following 
assessment (n=433) 
(3) Normal (n=9360)  
Median (IQR) PlGF:  
(1) = 166.4 (89.3-
277.9), (2) = 369.8 
(211.5-668.0), (3) = 
580.1 (348.5-
930.8) 
Yes 
p<0.025 
N/A - only 
reported in 
combination 
with other 
factors  
Fadigas 
2015 (31) 
SGA: BW <5th  (1) SGA without PET 
(n=158) 
(2) Normal/AGA 
without PET 
(n=3701)  
Median (IQR) PlGF:  
(1) = 195.6 (106.8-
377.6) vs (2) = 
320.2 (181.2-
576.6) 
Yes 
p<0.05 
N/A - only 
reported in 
combination 
with other 
factors  
Griffin 2015 
(30) 
SGA: BW <3rd 
(or <10th as 
secondary 
analysis)  
(1) SGA <3rd centile 
(n=78) 
(2) SGA <10th centile 
(n=192) 
(3) AGA >10th 
centile (n=400)  
Median PlGF (IQR):  
(1) = 94.5(36.3-
324), (2) = 
253(125-631), (3) = 
311(131-742) 
p value not 
reported 
(trend) 
PlGF <5th to 
predict SGA 
<3rd: 
Sens = 
37.2%  
Spec = 
88.7%  
PPV = 33.3%  
NPV = 90.3   
AUROC = 
0.70  
Lesmes 
2015 (29) 
SGA: BW <5th  (1) SGA <37w (n=46) 
(2) SGA >37w 
(n=435) 
(3) Control (n= 
9234).    
Median (IQR) PlGF:  
(1) = 214.8 (111.8-
266.1), (2) = 293.9 
(214.2-409.5), (3) = 
305.6 (220.8-
428.6) 
Yes 
p<0.025 
N/A - only 
reported in 
combination 
with other 
factors  
Gutaj 2014 
(35) 
SGA: BW <10th  (1) SGA (n=11)  
(2) non-SGA (n=48) 
Median PlGF (IQR):  
22-25wks: (1) = 
63.34 (12.79-
119.16) vs (2) = 
116.75 (33.93-
235.82)  
No (trend) 
p=0.07 
N/A    
Herraiz 
2014 (34) 
FGR: EFW <10th 
+ AFI<10th (in 
absence of 
PROM) or UA-PI 
>95th  
(1) Early FGR <34w 
(n=19) vs (2) Healthy 
controls (n=69). (3) 
Late FGR >34w (n=8) 
vs (4) Healthy 
controls (n=102) 
Median PlGF (IQR): 
(1) = 45.4 (29.6-
71.3) vs (2) = 531.0 
(337.2-775.0).  
(3) = 63.4 (41.3-
133.4) vs (4) = 
229.6 (133.0-
422.9) 
Yes 
p<0.001 & 
p<0.05 
 
N/A - only 
sFlt-1/PlGF 
ratio 
reported 
Nucci 2014 
(33) 
SGA: BW <5th  (1) SGA >37 weeks 
(n=99)  
(2) Controls (n=298) 
Median (IQR) 
MoM PlGF-1: 
@30-34w : (1) 
7.190 (3.741-
12.453) vs (2) 
12.820 (7.897-
18.653) 
@20-24w: (1) 
5.752 (4.198-
8.740) vs (2) 6.594 
(4.700-8.777) 
Yes @30-
34w 
p<0.025 
No (trend) 
@20-24w 
p=ns 
PlGF-1 to 
predict late 
SGA:  
AUROC = 
0.690  
DR for 10% 
FPR = 33.3  
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Boucoiran 
2013 (37) 
SGA: BW<10th  (1) SGA (n=56)  
(2) Unaffected 
(n=533) 
Median (IQR) 
MoM:  
(1) 0.55(0.40-0.89) 
vs (2) 0.95(0.63-
1.61)  
Yes 
p<0.05 
PlGF to 
predict SGA:  
AUROC = 
0.66  
DR = 23% 
Rizos 2013 
(36) 
SGA: BW ≤10th + 
normal AFI + 
normal UA 
Doppler in 3rd 
trimester 
(1) SGA (n=14)  
(2) Normal (n=90) 
Median (IQR) PlGF:  
2nd Tri: (1) = 290 
(189-450) vs (2) = 
311 (243-440) 
3rd Tri: (1) = 512 
(294-971) vs (2) = 
780 (472-1037)   
No (trend) 
P=ns 
N/A 
Mijal 2012 
(38) 
SGA: BW≤10th  (1) SGA-only (n=97)  
(2) Referent group 
(n=801) 
LS-mean (95%CI) 
PlGF:  
(1) 293.4 (256.8-
335.2) vs (2) 397.3 
(381.2-414.1) 
Yes 
p<0.0001 
N/A – only 
reported for 
prediction 
of PTB not 
SGA 
Stepan 
2007 (40) 
FGR: BW <5th + 
≥ 1 sign of 
disturbed 
placental 
function (e.g. 
oligohydramnios, 
UA-PI >90th)  
(1) FGR (n=13)  
(2) Normal outcome 
(n=38) 
Mean (±SEM) 
PlGF: 
(1) = 155.5 (33) vs 
(2) = 184.1 (21)  
No (trend) 
p=ns 
PlGF to 
predict FGR:  
Sens = 0.36 
Spec = 0.84 
PPV = 0.40 
Wallner 
2007 (39) 
FGR: AC <5th 
centile 
antenatally, BW 
<10th  
(1) FGR (n=16)  
(2) Control (n=16) 
Mean (+/- SD) 
PlGF: 
(1) = 48.44 (41.63) 
vs (2) = 245.74 
(217.42) 
Yes 
p=0.0017 
N/A 
Bersinger 
2004 (41) 
SGA: BW ≥2SD 
below expected 
weight, without 
malformations 
(1) SGA (n=25, 
samples @ K25=14, 
@K33=13)  
(2) Controls (n=65, 
samples @K25=41, 
@K33=49) 
Mean PlGF  
@25wk: (1) higher 
than (2)  
@33wk: (1) lower 
than (2) 
No at 25w 
p=ns 
Yes at 33w 
p=0.0487 
N/A 
Taylor 2003 
(42) 
SGA: BW <10th  (1) SGA ( n=18)  
(2) Controls (n=18)  
Median PlGF C-S: 
(1) ~200 vs (2) 
~350 
Yes 
p=0.04 
N/A 
 
PlGF – placental growth factor; SGA – small for gestational age; BW – birth weight; FGR – fetal growth 
restriction; EFW – estimated fetal weight; UA-PI – umbilical artery-pulsatility index; CPR – cerebro-placental 
ratio; AFI – Amniotic Fluid Index; PROM – premature rupture of membranes; AC – abdominal circumference; 
AGA – appropriate for gestational age; PET – preeclampsia; SD – standard deviations; PTB – preterm birth; 
<3rd, <5th, <10th – BW centiles adjusted for gestational age and sex; AUROC – area under receiver operator 
characteristic curve; Sens – sensitivity; Spec – specificity; PPV – positive predictive value; NPV – negative 
predictive value; OR – odds ratio; CI – confidence interval; DR – detection rate; N/A – data not available 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
23 
 
 
Table 3. PlGF for prediction of other adverse obstetric or perinatal outcomes 
Study Groups 
compared 
CS for 
fetal 
compro
mise 
Apgar 
<7 at 
5min 
NICU Neonat
al 
acidosi
s  
Stillbirth PTB 
<37w 
Advers
e 
compos
ite  
IFC  
Cetin 
2017 
(43) 
In FGR 
cohort 
adverse 
outcome 
occurred 
for: (1) 
very low 
PlGF 
(<12pg/ml
) (n=6), (2) 
low (12-
100) 
(n=4), (3) 
normal 
(≥100) 
(n=6) 
(1) 
5(83%), 
(2) 
3(75%), 
(3) 
2(33%), 
ns. 
N/A N/A a(1) 
7.31± 
0.03, 
(2) 
7.28± 
0.10, 
(3) 
7.31± 
0.10, 
ns. 
N/ABorc
hert 
N/A N/A N/A 
Bento
n 2016 
(10)  
placen
ta 
analysi
s 
Adverse 
outcome 
occurred 
for: (1) 
low PlGF 
(<5th 
centile) 
(n=94) vs 
(2) normal 
PlGF 
(n=119) 
*b (1) 
28(29.8%
) vs (2) 
10(8.4%), 
p<0.001. 
*(1) 
12(12.8
%) vs 
(2) 
1(0.8%)
, 
p<0.00
1. 
*c (1) 
26(27.7
%) vs 
(2) 
12(10.1
%), 
p<0.05. 
N/A *(1) 
6(6.4%) 
vs (2) 
0(0%), 
p<0.05. 
*(1) 
58(61.7
%) vs 
(2) 22 
(18.5%)
, 
p<0.001
. 
N/A N/A 
Bento
n 2016 
(10)  
deliver
y 
analysi
s  
Adverse 
outcome 
occurred 
for: (1) 
low PlGF 
(<5th 
centile) 
(n=157) vs 
(2) normal 
PlGF 
(n=254)  
*b (1) 
41(26.1%
) vs (2) 
19(7.5%), 
p<0.001. 
*(1) 
14(8.9
%) vs 2. 
2(0.8%)
, 
p<0.00
1. 
*c (1) 
31(19.7
%) vs 
(2) 
15(5.9%
), 
p<0.001
. 
N/A *(1) 
6(3.8%) 
vs (2) 
1(0.4%), 
p<0.05. 
*(1) 
79(50.3
%) vs 
(2) 
33(13.0
%), 
p<0.001
. 
N/A N/A 
Bligh 
2016 
(8) 
PlGF 
Median 
(IQR) for: 
(1) 
adverse 
outcome 
occurred 
vs (2) 
adverse 
outcome 
Only 
reported 
in 
conjuncti
on with 
instrume
ntal for 
IFC. 
*(1) 
80(64-
124) vs 
(2) 
128(80-
263), 
p=0.02. 
d (1) 
118(86-
154) vs 
(2) 
125(79-
263), 
p=0.70. 
*e (1) 
94(69-
124) vs 
(2) 
132(85-
228), 
p=0.02. 
N/A N/A *f (1) 
94(70-
142) vs 
(2) 
140(83-
270), 
p=0.002
. 
*g (1) 
90(67-
186) 
vs (2) 
139(8
4-
265), 
p=0.0
03. 
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did not 
occur 
(N=342) 
Valino 
2016 
(13) 
30-
34wks 
PlGF MoM 
(IQR) for: 
(1) 
adverse 
outcome 
occurred 
vs (2) 
adverse 
outcome 
did not 
occur 
(N=8268) 
During 
labour: 
(1) 
(n=512) 
0.94(0.52
-1.58) vs 
(2) 
(n=6263) 
0.95(0.58
-1.51), 
p=ns.  
*Before 
labour: 
(1) (n=30) 
0.24(0.11
-0.42) vs 
(2), 
p<0.0001
. 
(1) 
(n=70) 
1.13(0.
56-
1.71) vs 
(2) 
(n=705
4) 
0.94(0.
57-
1.50), 
ns. 
*d (1) 
(n=524) 
0.83(0.
40-
1.47) vs 
(2) 
(n=772
1) 
0.95(0.
58-
1.51), 
P<0.000
1. 
h (1) 
(n=84) 
1.01(0.
49-
1.49) vs 
(2) 
(n=324
4) 
0.94(0.
57-
1.52), 
ns. 
(1) 
(n=23) 
0.63(0.45
-1.31) vs 
(2) 
(n=7207) 
1.01(0.63
-1.57), 
ns. 
N/A N/A N/A 
Valino 
2016 
(25) 
35-
37wks 
PlGF MoM 
(IQR) for 
(1) 
adverse 
outcome 
occurred 
vs (2) 
adverse 
outcome 
did not 
occur 
(N=3953) 
During 
labour: 
(1) 
(n=275) 
0.90(0.49
-1.76) vs 
(2) 
(n=317) 
0.98(0.55
-1.68), 
p=ns.  
*Before 
labour: 
(1) (n=7) 
0.34(0.10
-1.36) vs 
(2), 
p<0.01. 
(1) 
(n=20) 
1.15(0.
67-
2.25) vs 
(2) 
(n=358
6) 
0.96(0.
55-
1.67), 
ns. 
d (1) 
(n=232) 
0.94(0.
54-
1.71) vs 
(2) 
(n=372
1) 
0.98(0.
55-
1.68), 
ns. 
h (1) 
(n=52) 
0.70(0.
43-
1.52) vs 
(2) 
(n=133
6) 
0.95(0.
53-
1.68), 
ns. 
N/A N/A N/A N/A 
Lobma
ier 
2014 
(14) 
In SGA 
cohort 
adverse 
outcome 
occurred 
for: (1) 
abnormal 
(<0.125M
oM) PlGF 
vs (2) 
normal 
PlGF 
(N=186) 
N/A N/A N/A N/A N/A N/A *i (1) 
~45% vs 
(2) 
~28%, 
p<0.05. 
AUC 
0.656 
(95%CI 
0.574-
0.737). 
N/A 
Mijal 
2012 
(38) 
adjusted 
OR for 
low PlGF 
N/A N/A N/A N/A N/A sPTB = 
1.12 
(95%CI 
N/A N/A 
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(<25th 
centile) 
(N=801) 
0.69-
1.83).  
MI-PTB 
= 1.32 
(95%CI 
0.56-
3.09). 
CS – caesarean section; IFC – intrapartum fetal compromise; NICU – neonatal intensive care unit; PTB – 
preterm birth; FGR – fetal growth restriction; SGA – small for gestational age; MoM – multiples of the median; 
IQR – interquartile range; OR – odds ratio; AUC – area under curve; CI – confidence interval; sPTB – 
spontaneous preterm birth; MI-PTB – medically indicated preterm birth; N/A – data not available; ns – not 
significant. 
* significant and p-value reported  
a Reported as cord umbilical artery pH mean value ±standard deviation 
b Fetal distress defined as absent or reversed end diastolic flow and/or an abnormal heart rate tracing during 
intrapartum monitoring 
c NICU admission >48 hours 
d Any NICU admission  
e Acidosis defined as cord umbilical artery pH≤7.1 or lactate≥6 
f Adverse neonatal composite defined as abnormal cord gases and/or Apgar ≤7 at 5min and/or NICU admission  
g IFC defined as intrapartum fetal heart rate abnormalities and/or abnormal fetal scalp lactate requiring 
emergency delivery - CS or instrumental 
h Acidosis defined as cord umbilical artery pH≤7.0 
i Adverse composite defined as operative delivery for non-reassuring fetal status or neonatal acidosis (umbilical 
artery pH<7.15 and base excess>12) 
~Actual values not reported - in bar graph only 
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